In this systematic review, GLP1-RAs were found to reduce weight in our meta-analysis by approximately 10 kg (∼TBW 10%) after >3-6 months of follow-up in IBD patients treated with semaglutide, liraglutide, or tirzepatide. This evidence concerns the gene GCG and inflammatory bowel disease.